Wu Jie, Wei Ying, Zhao Zhen-Long, Cao Shi-Liang, Li Yan, Peng Li-Li, Li Shu-Qi, Yu Ming-An
China-Japan Friendship Hospital, Beijing, China.
Front Endocrinol (Lausanne). 2025 Apr 25;16:1580765. doi: 10.3389/fendo.2025.1580765. eCollection 2025.
The aim of this study is to evaluate the efficacy and safety of microwave ablation (MWA) for cervical lymph node metastasis (LNM) in initially treated, post-ablation and post-resection papillary thyroid cancer (PTC) patients.
A total of 131 patients with 535 LNM from PTC who underwent ultrasound-guided MWA were included in the retrospective study. Patients were divided into three subgroups on the basis of treatment timing: initially treated, after PTC ablation (post-ablation), or after resection (post-resection). Changes in cervical metastatic lymph nodes as well as the incidences of complications, tumour recurrence and progression were compared.
The technical success rate of this study was 100% (535/535). Compared with those before MWA, the mean largest diameter and volume of the metastatic lymph nodes were significantly lower (p <0.01) at each follow-up. Transient hoarseness was the exclusive major complication with a total rate of 5.3% (9/171), which significantly differed in terms of incidence among the three subgroups (p<0.01). Lymph node location in region VI was an independent risk factor for transient hoarseness. The total recurrence rate was 22.8% (39/171) without statistically significant difference among the three sub-groups (p=0.20). Two cases received repeated surgery, while re-ablation was conducted successfully in all rest of cases. Data from the latest follow-up revealed one death due to LNM.
MWA is a safe and effective treatment option for LNM in initially treated, post-resection and post-ablation PTC patients.
本研究旨在评估微波消融(MWA)对初治、消融后及切除后乳头状甲状腺癌(PTC)患者颈部淋巴结转移(LNM)的疗效和安全性。
本回顾性研究纳入了131例接受超声引导下MWA治疗的PTC伴535处LNM患者。根据治疗时机将患者分为三个亚组:初治、PTC消融后(消融后)或切除后(切除后)。比较颈部转移性淋巴结的变化以及并发症、肿瘤复发和进展的发生率。
本研究的技术成功率为100%(535/535)。与MWA治疗前相比,每次随访时转移性淋巴结的平均最大直径和体积均显著降低(p<0.01)。短暂性声音嘶哑是唯一的主要并发症,总发生率为5.3%(9/171),在三个亚组中的发生率有显著差异(p<0.01)。Ⅵ区的淋巴结位置是短暂性声音嘶哑的独立危险因素。总复发率为22.8%(39/171),三个亚组之间无统计学显著差异(p=0.20)。2例患者接受了再次手术,其余所有病例均成功进行了再次消融。最新随访数据显示有1例患者因LNM死亡。
MWA是初治、切除后及消融后PTC患者LNM的一种安全有效的治疗选择。